Skip to main content
Figure 5 | BMC Biotechnology

Figure 5

From: Human TGFalpha-derived peptide TGFalphaL3 fused with superantigen for immunotherapy of EGFR-expressing tumours

Figure 5

TGFαL3SEA D227A recruits T cells to the tumour tissue. Tumour tissues were excised from mice treated with 60 pmol TGFαL3SEAD227A or PBS after 24 days. The histochemical samples were prepared in a standard way, followed by staining with antibodies against the CD4 molecule (A and B) or the CD8 molecule (C and D). CD4+ and CD8+ T cells in the PBS control group were shown in figure 5B and 5 D, respectively; CD4+ and CD8+ T cells in the TGFαL3SEAD227A group are shown in figure 5A and 5C, respectively.

Back to article page